Bristol Pleads Guilty To Criminal Charges To Settle DoJ Investigation Over Plavix
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol will pay $1 million to close an investigation related to the renegotiation of a generic settlement with Apotex over Plavix.
You may also be interested in...
Apotex Plavix Saga May Finally Be Over; Judge Asks “What Is Going On In This Case?”
Apotex sought $3.4 billion in damages, claiming Bristol-Myers Squibb scuttled their patent settlement agreement by submitting a false certification to the FTC that it had no oral commitment not to sell an authorized generic of Plavix during Apotex’s exclusivity period; Apotex had told the FTC there was such a side deal.
Plavix Takes A Final Bow, But Will It Go Gracefully?
Generic versions of Bristol-Myers Squibb/Sanofi’s blockbuster clot-buster clopidogrel launched in the U.S. May 17, but the companies are helping some patients continue on the brand by covering the high out-of-pocket costs. Following Pfizer’s success retaining share of Lipitor, industry is paying close attention to brand retention programs.
Apotex To Retain About $300 Million From Its At-Risk Launch of Generic Plavix
A judge sets damages at 50% of Apotex's net sales of generic clopidogrel plus prejudgment interest of $107.9 million.